Reversine induces cell cycle arrest and apoptosis via upregulation of the Fas and DR5 signaling pathways in human colorectal cancer cells

Park,Young-Lan; Ha,Sang-Yoon; Park,Sun-Young; Choi,Jung-Ho; Jung,Min-Woo; Myung,Dae-Seong; Kim,Hyun-Soo; Joo,Young-Eun

doi:10.3892/ijo.2019.4746

Reversine induces cell cycle arrest and apoptosis via upregulation of the Fas and DR5 signaling pathways in human colorectal cancer cells

Authors:
- Young-Lan Park
- Sang-Yoon Ha
- Sun-Young Park
- Jung-Ho Choi
- Min-Woo Jung
- Dae-Seong Myung
- Hyun-Soo Kim
- Young-Eun Joo
View Affiliations

Affiliations: Department of Internal Medicine, Chonnam National University Medical School, Gwangju 501-757, Republic of Korea
Published online on: March 13, 2019 https://doi.org/10.3892/ijo.2019.4746
Pages: 1875-1883

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Reversine, a 2,6‑diamino‑substituted purine analogue, has been reported to be effective in tumor suppression via induction of cell growth arrest and apoptosis of cancer cells. However, it remains unclear whether reversine exerts anticancer effects on human colorectal cancer cells. In the present study, in vitro experiments were conducted to investigate the anticancer properties of reversine in human colorectal cancer cells. The effect of reversine on human colorectal cancer cell lines, SW480 and HCT‑116, was examined using a WST‑1 cell viability assay, fluorescence microscopy, flow cytometry, DNA fragmentation, small interfering RNA (siRNA) and western blotting. Reversine treatment demonstrated cytotoxic activity in human colorectal cancer cells. It also induced apoptosis by activating poly(ADP‑ribose) polymerase, caspase‑3, ‑7 and ‑8, and increasing the levels of the pro‑apoptotic protein second mitochondria‑derived activator of caspase/direct inhibitor of apoptosis‑binding protein with low pI. The pan‑caspase inhibitor Z‑VAD‑FMK attenuated these reversine‑induced apoptotic effects on human colorectal cancer cells. Additionally, reversine treatment induced cell cycle arrest in the subG1 and G2/M phases via increase in levels of p21, p27 and p57, and decrease in cyclin D1 levels. The expression of Fas and death receptor 5 (DR5) signaling proteins in SW480 and HCT116 cells was upregulated by reversine treatment. Reversine‑induced apoptosis and cell cycle arrest were suppressed by inhibition of Fas and DR5 expression via siRNA. In conclusion, Reversine treatment suppressed tumor progression by the inhibition of cell proliferation, induction of cell cycle arrest and induction of apoptosis via upregulation of the Fas and DR5 signaling pathways in human colorectal cancer cells. The present study indicated that reversine may be used as a novel anticancer agent in human colorectal cancer.

View Figures

View References

1	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014.
2	Choi Y, Sateia HF, Peairs KS and Stewart RW: Screening for colorectal cancer. Semin Oncol. 44:34–44. 2017.
3	Chen S, Zhang Q, Wu X, Schultz PG and Ding S: Dedifferentiation of lineage-committed cells by a small molecule. J Am Chem Soc. 126:410–411. 2004.
4	Chen S, Takanashi S, Zhang Q, Xiong W, Zhu S, Peters EC, Ding S and Schultz PG: Reversine increases the plasticity of lineage-committed mammalian cells. Proc Natl Acad Sci USA. 104:10482–10487. 2007.
5	Lee EK, Bae GU, You JS, Lee JC, Jeon YJ, Park JW, Park JH, Ahn SH, Kim YK, Choi WS, et al: Reversine increases the plasticity of lineage-committed cells toward neuroectodermal lineage. J Biol Chem. 284:2891–2901. 2009.
6	Pikir BS, Susilowati H, Hendrianto E and Abdulrantam F: Reversin increase the plasticity of bone marrow-derived mesenchymal stem cell for generation of cardiomyocyte in vitro. Acta Med Indones. 44:23–27. 2012.
7	Yan M, Wang C, He B, Yang M, Tong M, Long Z, Liu B, Peng F, Xu L, Zhang Y, et al: Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy. Med Res Rev. 36:1036–1079. 2016.
8	Tang A, Gao K, Chu L, Zhang R, Yang J and Zheng J: Aurora kinases: Novel therapy targets in cancers. Oncotarget. 8:23937–23954. 2017.
9	Malumbres M and Pérez de Castro I: Aurora kinase A inhibitors: Promising agents in antitumoral therapy. Expert Opin Ther Targets. 18:1377–1393. 2014.
10	Hsieh TC, Traganos F, Darzynkiewicz Z and Wu JM: The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells. Int J Oncol. 31:1293–1300. 2007.
11	Lu CH, Liu YW, Hua SC, Yu HI, Chang YP and Lee YR: Autophagy induction of reversine on human follicular thyroid cancer cells. Biomed Pharmacother. 66:642–647. 2012.
12	Piccoli M, Palazzolo G, Conforti E, Lamorte G, Papini N, Creo P, Fania C, Scaringi R, Bergante S, Tringali C, et al: The synthetic purine reversine selectively induces cell death of cancer cells. J Cell Biochem. 113:3207–3217. 2012.
13	Kuo CH, Lu YC, Tseng YS, Shi CS, Chen SH, Chen PT, Wu FL, Chang YP and Lee YR: Reversine induces cell cycle arrest, polyploidy, and apoptosis in human breast cancer cells. Breast Cancer. 21:358–369. 2014.
14	Bosco B, Defant A, Messina A, Incitti T, Sighel D, Bozza A, Ciribilli Y, Inga A, Casarosa S and Mancini I: Synthesis of 2,6-diamino-substituted purine derivatives and evaluation of cell cycle arrest in breast and colorectal cancer cells. Molecules. 23:E19962018.
15	Cheng L, Wang H, Guo K, Wang Z, Zhang Z, Shen C, Chen L and Lin J: Reversine, a substituted purine, exerts an inhibitive effect on human renal carcinoma cells via induction of cell apoptosis and polyploidy. OncoTargets Ther. 11:1025–1035. 2018.
16	Qin HX, Yang J, Cui HK, Li SP, Zhang W, Ding XL and Xia YH: Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo. Cytotechnology. 65:643–653. 2013.
17	Rodrigues Alves AP, Machado-Neto JA, Scheucher PS, Paiva HH, Simões BP, Rego EM and Traina F: Reversine triggers mitotic catastrophe and apoptosis in K562 cells. Leuk Res. 48:26–31. 2016.
18	Lu YC, Lee YR, Liao JD, Lin CY, Chen YY, Chen PT and Tseng YS: Reversine induced multinucleated cells, cell apoptosis and autophagy in human non-small cell lung cancer cells. PLoS One. 11:e01585872016.
19	Lee YR, Wu WC, Ji WT, Chen JY, Cheng YP, Chiang MK and Chen HR: Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy. J Biomed Sci. 19:92012.
20	D’Alise AM, Amabile G, Iovino M, Di Giorgio FP, Bartiromo M, Sessa F, Villa F, Musacchio A and Cortese R: Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol Cancer Ther. 7:1140–1149. 2008.
21	Jemaà M, Abassi Y, Kifagi C, Fezai M, Daams R, Lang F and Massoumi R: Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1. Sci Rep. 8:118212018.
22	Hua SC, Chang TC, Chen HR, Lu CH, Liu YW, Chen SH, Yu HI, Chang YP and Lee YR: Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells. Pharm Res. 29:1990–2005. 2012.
23	Bijian K, Lougheed C, Su J, Xu B, Yu H, Wu JH, Riccio K and Alaoui-Jamali MA: Targeting focal adhesion turnover in invasive breast cancer cells by the purine derivative reversine. Br J Cancer. 109:2810–2818. 2013.
24	Kiechle FL and Zhang X: Apoptosis: Biochemical aspects and clinical implications. Clin Chim Acta. 326:27–45. 2002.
25	Schultz DR and Harrington WJ Jr: Apoptosis: Programmed cell death at a molecular level. Semin Arthritis Rheum. 32:345–369. 2003.
26	Llambi F and Green DR: Apoptosis and oncogenesis: Give and take in the BCL-2 family. Curr Opin Genet Dev. 21:12–20. 2011.
27	Lim S and Kaldis P: Cdks, cyclins and CKIs: Roles beyond cell cycle regulation. Development. 140:3079–3093. 2013.
28	Soták M, Sumová A and Pácha J: Cross-talk between the circadian clock and the cell cycle in cancer. Ann Med. 46:221–232. 2014.
29	Bonelli P, Tuccillo FM, Borrelli A, Schiattarella A and Buonaguro FM: CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity. BioMed Res Int. 2014:3610202014.
30	Wang K, Baldwin GS, Nikfarjam M and He H: p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World J Gastroenterol. 24:3709–3723. 2018.
31	Bencivenga D, Caldarelli I, Stampone E, Mancini FP, Balestrieri ML, Della Ragione F and Borriello A: p27Kip1 and human cancers: A reappraisal of a still enigmatic protein. Cancer Lett. 403:354–365. 2017.
32	Kobatake T, Yano M, Toyooka S, Tsukuda K, Dote H, Kikuchi T, Toyota M, Ouchida M, Aoe M, Date H, et al: Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep. 12:1087–1092. 2004.
33	Villa-Morales M and Fernández-Piqueras J: Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:85–101. 2012.
34	Mocellin S: Targeting death receptors to fight cancer: From biological rational to clinical implementation. Curr Med Chem. 17:2713–2728. 2010.
35	Tschumi BO, Dumauthioz N, Marti B, Zhang L, Schneider P, Mach JP, Romero P and Donda A: CART cells are prone to Fas- and DR5-mediated cell death. J Immunother Cancer. 6:712018.
36	Wang X, Xue Q, Wu L, Wang B and Liang H: Dasatinib promotes TRAIL-mediated apoptosis by upregulating CHOP-dependent death receptor 5 in gastric cancer. FEBS Open Bio. 8:732–742. 2018.
37	Shlyakhtina Y, Pavet V and Gronemeyer H: Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells. Cell Death Dis. 8:e30252017.
38	Karbasi A, Borhani N, Daliri K, Kazemi B and Manoochehri M: Downregulation of external death receptor genes FAS and DR5 in colorectal cancer samples positive for human papillomavirus infection. Pathol Res Pract. 211:444–448. 2015.